Click Therapeutics

Click Therapeutics, Inc. is a company focused on the development and commercialization of digital therapeutics designed to address various unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company creates software solutions that can serve as medical treatments, either independently or alongside traditional biomedical therapies. Click Therapeutics targets a range of conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Their innovative Clickometrics® platform continuously personalizes user experiences to enhance engagement and treatment outcomes. One of their notable products, a smoking cessation program, is available nationwide through various healthcare payers and providers. Additionally, Click's lead prescription program is currently undergoing a phase III clinical trial for the treatment of Major Depressive Disorder in adults, reflecting its commitment to advancing therapeutic options in mental health and other areas.